Compared to the peak of the Yieldco bubble in May, many Yieldcos have dropped by more than half, and most by more than a third. Some of this decline is because rapid dividend growth depends on an endless supply of cheap investor capital– which is another way of saying that we can have rapid dividend…
I’ve touted Pier One many times as a short idea (recently, here) since the analog was so breathtakingly good. May I present to you an update of my goofy idea:
Yesterday, Janet Yellen announced the first hike in the Fed Funds rate in eleven years from .25% to .50%. When asked about why the Fed decided to raise rates now, Ms. Yellen responded by suggesting that the “odds were good” the economy would have ended up overshooting the Fed’s employment, growth and inflation goals had rates remained…
Despite sporadic algo-crazed ramps, crude oil prices continue to slide back towards a $34 handle (in Jan ’16 contract) this morning following a reiterated downbeat note from Goldman warning that storage levels are “too full for comfort,” that positioning is not as stretched short as some believe, and confirming that this will not end until prices near cash…
The data for this series is remains soft with the rolling averages remaining in contraction year-over-year – although imports did expand year-over-year comparing this month to the same month one year ago. This continues to indicate weak economic conditions domestically and globally. Consider that imports final sales are added to GDP usually several months after…
Did the Fed make a mistake by raising rates yesterday? I will leave that answer to people that are much smarter than me. From a Power of the Pattern perspective, what the Transports do at dual support above could say a ton about where the broad markets head from here. Humbly, this does NOT look…
Today AstraZeneca (AZN) announced that it has bought a $4 billion stake in a private pharmaceutical company known as Acerta Pharma. The reason for this acquisition is for the company to boost its blood cancer product pipeline. Acerta’s blood cancer drug, known as Acalabrutinib, is used for the treatment of blood cancers. That drug is…
Heineken (HEINY) could be acquiring a brand which will boost its market share and profitability. Anheuser-Busch InBev (BUD) is planning on selling some of its premium brands such as Peroni and Grolsch, with Heineken being a potential buyer. This could boost their share price as they acquire these premium brands. Earlier this month AB InBev…
Written by Joseph Joyce The seventh edition of Manias, Panics, and Crashes has recently been published by Palgrave Macmillan. Charles Kindleberger of MIT wrote the first edition, which appeared in 1978, and followed it with three more editions. Robert Aliber of the Booth School of Business at the University of Chicago took over the editing and rewriting…
Heading into the Fed’s first “dovish” rate hike in nearly a decade, the consensus was two-fold: as a result of relentless telegraphing of the Fed’s intentions, the hike is priced in, and it will be a “dovish” hike, with the Fed lowering its forecast for the number of hikes over the next year. Consensus was…
